MAM
MRTX

Meeder Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Meeder Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 2425
2022
Q2 		$0 Sell
2
-24
-92% -$1.53K ﹤0.01% 2493
2022
Q1 		$2K Buy
+26
New +$2.66K ﹤0.01% 2111
2021
Q4 		– Sell
-2,322
Closed -$410K – 2470
2021
Q3 		$410K Buy
+2,322
New +$374K 0.02% 501
2021
Q2 		– Sell
-386
Closed -$66K – 2714
2021
Q1 		$66K Buy
+386
New +$76.4K ﹤0.01% 1028
2020
Q4 		– Sell
-2,239
Closed -$371K – 2309
2020
Q3 		$371K Buy
2,239
+2,238
+223,800% +$306K 0.02% 449
2020
Q2 		$0 Buy
+1
New +$97 ﹤0.01% 2576
2020
Q1 		– Sell
-339
Closed -$44K – 2590
2019
Q4 		$44K Buy
339
+6
+2% +$579 ﹤0.01% 1061
2019
Q3 		$26K Sell
333
-1,167
-78% -$110K ﹤0.01% 1228
2019
Q2 		$154K Sell
1,500
-752
-33% -$58.5K 0.01% 647
2019
Q1 		$166K Buy
2,252
+165
+8% +$11.2K 0.01% 581
2018
Q4 		$89K Buy
2,087
+239
+13% +$9.52K 0.01% 669
2018
Q3 		$88K Buy
+1,848
New +$103K 0.01% 676
2017
Q4 		– Sell
-396
Closed -$5K – 1832
2017
Q3 		$5K Sell
396
-247
-38% -$1.43K ﹤0.01% 1291
2017
Q2 		$2K Sell
643
-599
-48% -$2.29K ﹤0.01% 1445
2017
Q1 		$6K Sell
1,242
-492
-28% -$2.7K ﹤0.01% 1028
2016
Q4 		$8K Buy
+1,734
New +$9.43K ﹤0.01% 802

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Meeder Asset Management's MRTX Position: Q3 2022 in Review

Meeder Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022, closing a stake of 2 shares.

Meeder Asset Management first reported a position in MRTX in Q4 2016 and held it in 16 quarters. The position peaked at $410K in Q3 2021. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

  • Meeder Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Meeder Asset Management sold 2 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Meeder Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2016 and held it in 16 quarters.
  • Meeder Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $410K in Q3 2021.
  • 243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Meeder Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.